Compare LQDT & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LQDT | ANAB |
|---|---|---|
| Founded | 1999 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.4B |
| IPO Year | 2005 | 2015 |
| Metric | LQDT | ANAB |
|---|---|---|
| Price | $44.60 | $47.44 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | $51.00 | ★ $87.25 |
| AVG Volume (30 Days) | 190.4K | ★ 447.0K |
| Earning Date | 11-19-2026 | 11-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 38.10 | ★ 91.02 |
| EPS | ★ 0.78 | N/A |
| Revenue | ★ $476,669,000.00 | $234,603,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $69.42 |
| P/E Ratio | $57.29 | ★ N/A |
| Revenue Growth | 31.20 | ★ 157.01 |
| 52 Week Low | $21.67 | $30.27 |
| 52 Week High | $45.92 | $73.30 |
| Indicator | LQDT | ANAB |
|---|---|---|
| Relative Strength Index (RSI) | 54.75 | 44.91 |
| Support Level | $36.82 | $44.38 |
| Resistance Level | $45.92 | $51.94 |
| Average True Range (ATR) | 1.06 | 2.27 |
| MACD | 0.01 | 0.25 |
| Stochastic Oscillator | 51.20 | 44.55 |
Liquidity Services Inc is an online auction marketplace. It manages and sells inventory and equipment for business and government clients by operating a network of e-commerce marketplaces that enable buyers and sellers to transact in an efficient, automated environment offering across different product categories. The company has four reportable segments: GovDeals, Retail Supply Chain Group (RSCG), and Machinio & Software Solutions. It generates majority of its revenue from Retail Supply Chain Group (RSCG) segment which consists of marketplaces that enable corporations located in the United States and Canada to sell excess, returned, and overstocked consumer goods. Geographically, a substantial portion the company's revenue is generated from its business in United States.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).